Innate immunity glycoprotein gp-340 variants may modulate human susceptibility to dental caries-1

<p><b>Copyright information:</b></p><p>Taken from "Innate immunity glycoprotein gp-340 variants may modulate human susceptibility to dental caries"</p><p>http://www.biomedcentral.com/1471-2334/7/57</p><p>BMC Infectious Diseases 2007;7():57-57.</p><p>Published online 11 Jun 2007</p><p>PMCID:PMC1894970.</p><p></p> caries-associated variables from modelling with caries experience in the children as dependent variable, and (B) gp-340 I to III phenotypes from modelling with saliva adhesion of in the children as dependent variable

Innate immunity glycoprotein gp-340 variants may modulate human susceptibility to dental caries-5

<p><b>Copyright information:</b></p><p>Taken from "Innate immunity glycoprotein gp-340 variants may modulate human susceptibility to dental caries"</p><p>http://www.biomedcentral.com/1471-2334/7/57</p><p>BMC Infectious Diseases 2007;7():57-57.</p><p>Published online 11 Jun 2007</p><p>PMCID:PMC1894970.</p><p></p> caries-associated variables from modelling with caries experience in the children as dependent variable, and (B) gp-340 I to III phenotypes from modelling with saliva adhesion of in the children as dependent variable

Innate immunity glycoprotein gp-340 variants may modulate human susceptibility to dental caries-0

<p><b>Copyright information:</b></p><p>Taken from "Innate immunity glycoprotein gp-340 variants may modulate human susceptibility to dental caries"</p><p>http://www.biomedcentral.com/1471-2334/7/57</p><p>BMC Infectious Diseases 2007;7():57-57.</p><p>Published online 11 Jun 2007</p><p>PMCID:PMC1894970.</p><p></p>stern blotting of parotid saliva samples with mAb143. Unreduced parotid saliva samples were separated by SDS-PAGE on 5% gels. Molecular masses (kDa, left) and gp-340 I to III phenotype (top) of the three saliva donors are marked

Innate immunity glycoprotein gp-340 variants may modulate human susceptibility to dental caries-4

<p><b>Copyright information:</b></p><p>Taken from "Innate immunity glycoprotein gp-340 variants may modulate human susceptibility to dental caries"</p><p>http://www.biomedcentral.com/1471-2334/7/57</p><p>BMC Infectious Diseases 2007;7():57-57.</p><p>Published online 11 Jun 2007</p><p>PMCID:PMC1894970.</p><p></p>stern blotting of parotid saliva samples with mAb143. Unreduced parotid saliva samples were separated by SDS-PAGE on 5% gels. Molecular masses (kDa, left) and gp-340 I to III phenotype (top) of the three saliva donors are marked

Innate immunity glycoprotein gp-340 variants may modulate human susceptibility to dental caries-2

<p><b>Copyright information:</b></p><p>Taken from "Innate immunity glycoprotein gp-340 variants may modulate human susceptibility to dental caries"</p><p>http://www.biomedcentral.com/1471-2334/7/57</p><p>BMC Infectious Diseases 2007;7():57-57.</p><p>Published online 11 Jun 2007</p><p>PMCID:PMC1894970.</p><p></p>2 ug/ml for fixed amounts of protein). Data are presented as mean ± SE from double measurements of repeated experimental runs. (A) Adhesion of Ingbritt to gp-340 I vs II or III (* p < 0.001, respectively). Similar results were obtained irrespective of culturing in BHI or Jordan broth. (B) Adhesion of NG8 and isogenic mutant 834, disrupted in the (AgI/II polypeptide) gene, to gp-340 I protein (* p < 0.001). (C) Adhesion of expressing SpaP (from ) or vector control (wild-type) MG1363 to serial dilutions of gp-340 I vs II or III (* p < 0.001, respectively). Similar results were obtained when expressing PAc was bound to serial dilutions of gp-340 I to III

Innate immunity glycoprotein gp-340 variants may modulate human susceptibility to dental caries-3

<p><b>Copyright information:</b></p><p>Taken from "Innate immunity glycoprotein gp-340 variants may modulate human susceptibility to dental caries"</p><p>http://www.biomedcentral.com/1471-2334/7/57</p><p>BMC Infectious Diseases 2007;7():57-57.</p><p>Published online 11 Jun 2007</p><p>PMCID:PMC1894970.</p><p></p>340 I versus II/III, median scores 4 and 0, respectively, p = 0.027). (B) Numbers of gp-340 I positive subjects (■) among Db+ and Db- subjects (* p = 0.051). (C) Caries experience (mean DMFS ± SE) in subjects positive for gp-340 I and Db (gp-340I/Db+) versus subjects negative for both proteins (gp-340II, III/Db-) (* p = 0.023)